Dashboard
Manage Tickers

APREAprea Therapeutics, Inc.


$ 2.91 $ -0.08 (-2.43 %)    

Tuesday, 17-Sep-2024 13:35:01 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 473.83 $ 0.25 (0.05 %)
DIA $ 417.12 $ -0.12 (-0.03 %)
SPY $ 563.14 $ 0.23 (0.04 %)
TLT $ 100.82 $ -0.49 (-0.48 %)
GLD $ 237.35 $ -1.32 (-0.55 %)
$ 3.01
$ 3.09
-- x --
-- x --
$ 2.91 - $ 3.09
$ 2.90 - $ 8.85
19,863
na
16.35M
$ 0.79
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

wedbush-reiterates-outperform-on-aprea-therapeutics-maintains-11-price-target
Wedbush Reiterates Outperform on Aprea The...
08/13/2024 14:34:10

Wedbush analyst Robert Driscoll reiterates Aprea Therapeutics (NASDAQ:APRE) with a Outperform and maintains $11 price target.

hc-wainwright--co-reiterates-buy-on-aprea-therapeutics-maintains-20-price-target
HC Wainwright & Co. Reiterates Buy on Apre...
08/12/2024 17:50:04

HC Wainwright & Co. analyst Joseph Pantginis reiterates Aprea Therapeutics (NASDAQ:APRE) with a Buy and maintains $20 pr...

aprea-therapeutics-q2-eps-058-beats-064-estimate-sales-56157k-beat-5000k-estimate
Aprea Therapeutics Q2 EPS $(0.58) Beats $(...
08/12/2024 12:41:23

Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(...

hc-wainwright--co-reiterates-buy-on-aprea-therapeutics-maintains-20-price-target
HC Wainwright & Co. Reiterates Buy on Apre...
06/24/2024 17:34:57

HC Wainwright & Co. analyst Joseph Pantginis reiterates Aprea Therapeutics (NASDAQ:APRE) with a Buy and maintains $20 pr...

aprea-therapeutics-to-host-virtual-kol-event-on-june-24-2024-to-discuss-apr-1051-a-selective-oral-wee1-inhibitor
Aprea Therapeutics To Host Virtual KOL Eve...
06/21/2024 12:12:20

Features Medicinal Chemistry Expert Joseph Vacca And University Of Pennsylvania's Eric J. Brown Discussing Preclinical Find...

aprea-therapeutics-to-host-virtual-kol-event-on-apr-1051
Aprea Therapeutics To Host Virtual KOL Eve...
06/21/2024 12:11:46

hc-wainwright--co-reiterates-buy-on-aprea-therapeutics-maintains-20-price-target
HC Wainwright & Co. Reiterates Buy on Apre...
06/17/2024 14:43:52

HC Wainwright & Co. analyst Joseph Pantginis reiterates Aprea Therapeutics (NASDAQ:APRE) with a Buy and maintains $20 pr...

aprea-therapeutics-doses-first-patient-in-phase-1-acesot-1051-study-of-oral-wee1-inhibitor-apr-1051-as-monotherapy-for-advanced-solid-tumors
Aprea Therapeutics Doses First Patient In ...
06/17/2024 12:34:35

aprea-therapeutics-safety-review-committee-endorses-dosing-patients-with-atrn-119-in-aboya-119-clinical-trial
Aprea Therapeutics Safety Review Committee...
05/28/2024 12:48:46

ATRN-119 is the first and only macrocyclic ATR inhibitor in the clinic, with best in class potential On track to complete dose ...

hc-wainwright--co-reiterates-buy-on-aprea-therapeutics-maintains-20-price-target
HC Wainwright & Co. Reiterates Buy on Apre...
05/14/2024 15:15:35

HC Wainwright & Co. analyst Joseph Pantginis reiterates Aprea Therapeutics (NASDAQ:APRE) with a Buy and maintains $20 pr...

aprea-therapeutics-q1-eps-067-beats-078-estimate-sales-38057k
Aprea Therapeutics Q1 EPS $(0.67) Beats $(...
05/14/2024 12:47:24

Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.67) per share which beat the analyst consensus estimate of $(...

aprea-therapeutics-announces-presentations-on-its-next-generation-wee1-inhibitor-apr-1051-and-a-novel-macrocyclic-atr-inhibitor-atrn-119-at-aacr-annual-meeting-2024
Aprea Therapeutics Announces Presentations...
04/10/2024 16:02:28

Pre-clinical findings underscore the potential of APR-1051, a next-generation WEE1 kinase inhibitor, to be a well-tolerated and...

12-health-care-stocks-moving-in-thursdays-pre-market-session
12 Health Care Stocks Moving In Thursday's...
04/04/2024 12:09:11

wedbush-maintains-outperform-on-aprea-therapeutics-raises-price-target-to-11
Wedbush Maintains Outperform on Aprea Ther...
03/27/2024 11:54:52

Wedbush analyst Robert Driscoll maintains Aprea Therapeutics (NASDAQ:APRE) with a Outperform and raises the price target fro...

hc-wainwright--co-maintains-buy-on-aprea-therapeutics-maintains-20-price-target
HC Wainwright & Co. Maintains Buy on Aprea...
03/26/2024 15:12:14

HC Wainwright & Co. analyst Joseph Pantginis maintains Aprea Therapeutics (NASDAQ:APRE) with a Buy and maintains $20 pri...

aprea-therapeutics-q4-earnings-insights
Aprea Therapeutics: Q4 Earnings Insights
03/26/2024 13:10:10

why-is-precision-oncology-focused-aprea-therapeutics-stock-trading-higher-on-monday
Why Is Precision Oncology-Focused Aprea Th...
03/11/2024 13:39:22

FDA clearance for Aprea Therapeutics' APR-1051 IND application, a promising WEE1 kinase inhibitor. Phase 1 trial initiation...

12-health-care-stocks-moving-in-mondays-pre-market-session
12 Health Care Stocks Moving In Monday's P...
03/11/2024 13:05:55

Core News & Articles
Market-Moving News for March 11th
03/11/2024 12:40:56

DUO: 151% | Fangdd Network shares are trading higher after the company announced its 2024 strategic layout with plans to enter ...

aprea-therapeutics-shares-are-trading-higher-after-the-company-announced-fda-clearance-of-its-ind-for-apr-1051-the-company-also-announced-private-placement-financing-of-up-to-34-million
Aprea Therapeutics shares are trading high...
03/11/2024 12:38:35

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION